Just diagnosed with Primary cutaneous amyloidosis?
You are not alone. Here is where to start: learn the basics, find a specialist or center that sees Primary cutaneous amyloidosis, look for clinical trials, and connect with others living with it — all in one place.
Open the full interactive Primary cutaneous amyloidosis hub →Overview
Primary cutaneous amyloidosis is a rare condition. Also known as PLCA, Primary localized cutaneous amyloidosis. Tomeko brings together the specialists, research, clinical trials, treatments and community for Primary cutaneous amyloidosis so you can go from overwhelmed to oriented. For authoritative medical detail, see the reference sources below.
Identifiers: ORPHA:137807 · GARD 0000132
Find care for Primary cutaneous amyloidosis
Authoritative references for Primary cutaneous amyloidosis
Research & market landscape for Primary cutaneous amyloidosis
Following Primary cutaneous amyloidosis for research or industry? Tomeko brings together the recruiting trials, the latest literature, patient organizations, and the specialist and care-center footprint for Primary cutaneous amyloidosis — the real-world landscape behind the condition, in one place.
- Latest Primary cutaneous amyloidosis research on PubMed ↗
- Recruiting Primary cutaneous amyloidosis trials on ClinicalTrials.gov ↗
- Explore the Primary cutaneous amyloidosis research & specialist footprint on Tomeko
Researchers, patient organizations & industry: Tomeko provides de-identified, no-PHI demand and engagement signal, trial awareness, and a labeled, editorially-firewalled presence for Primary cutaneous amyloidosis and every rare condition. See how Tomeko works with industry →
Common questions
What is Primary cutaneous amyloidosis?
Primary cutaneous amyloidosis is a rare condition. Also known as PLCA, Primary localized cutaneous amyloidosis. For an authoritative medical description see the reference sources on this page; Tomeko brings the specialists, clinical trials, patient organizations and community for Primary cutaneous amyloidosis together in one place.
What are the symptoms of Primary cutaneous amyloidosis?
Symptoms of Primary cutaneous amyloidosis vary from person to person. For a reviewed, plain-language overview see the authoritative references below (NIH GARD, Orphanet), and discuss your own symptoms with a clinician who treats Primary cutaneous amyloidosis.
How is Primary cutaneous amyloidosis treated?
Treatment for Primary cutaneous amyloidosis depends on the individual and is managed by specialists. Use Tomeko to find clinicians and Centers of Excellence who see Primary cutaneous amyloidosis, and review current options with them.
What causes Primary cutaneous amyloidosis — is it genetic?
The cause and inheritance of Primary cutaneous amyloidosis are described in the authoritative references linked on this page. A genetics or specialist clinician who treats Primary cutaneous amyloidosis can explain what it means for you and your family.
I was just diagnosed with Primary cutaneous amyloidosis — what should I do first?
Start by learning the basics from an authoritative source, find a specialist or center that sees Primary cutaneous amyloidosis, and connect with a patient organization. Tomeko brings these together on one hub.
Where can I find a specialist for Primary cutaneous amyloidosis?
Use Tomeko's specialist and Centers-of-Excellence directories to find clinicians who treat Primary cutaneous amyloidosis, filtered to your area.
Are there clinical trials for Primary cutaneous amyloidosis?
Tomeko shows live, recruiting studies for Primary cutaneous amyloidosis from ClinicalTrials.gov on the hub.
Related conditions
Other conditions on Tomeko you may be looking for:
- Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma
- Primary cutaneous anaplastic large cell lymphoma
- Primary congenital glaucoma
- Primary cutaneous B-cell lymphoma
- Primary condylar hyperplasia
- Primary cutaneous CD30+ T-cell lymphoproliferative disease
- Primary coenzyme Q10 deficiency 8
- Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma